CHF Solutions to Host Clinician Webinar on Use of Ultrafiltration for Volume Management in Patients Treated for COVID-19
Dr.
Webinar Details: Presenters
Amir Kazory, MD, FASN,
Learning Objectives:
- Discuss the WHO protocol and the importance of identifying volume overload in COVID-19 infected patients
- Understand the risks associated with volume overload, importance of maintaining fluid balance, and benefits of using ultrafiltration in patients with volume overload
- Discuss training and personnel required to quickly implement access to ultrafiltration
- Hear real-world critical care patient case studies
“It’s important that health care providers are aware of available, innovative technologies that can improve outcomes for their patients,” said Dr. Amir Kazory, MD, FASN,
“With potential surges in critically ill patients as a result of the COVID-19 pandemic, we want to ensure that clinicians understand and have access to our products, teams and advisors,” said
Register to participate in this informative webinar by following this link: www.bit.ly/2vhRW7z. For those unable to attend the webinar, an audio archive of the webcast and a transcript will be available at http://ir.chf-solutions.com/events within 48 hours after the event concludes.
About
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the clinical use of the Aquadex SmartFlow system in patients infected with the coronavirus COVID-19. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
________________________________________
1 WHO reference number: WHO/nCoV/Clinical/2020.3
CONTACTS
INVESTORS:
Chief Financial Officer,
952-345-4205
ir@chf-solutions.com
MEDIA:
Health+Commerce
617-817-1385
brad@healthandcommerce.com
Source: CHF Solutions, Inc.